Treatment with the selective COX-2 inhibitor celecoxib ameliorated T2DM-related NASH as shown by anti-inflammatory activity and restraining insulin resistance, probably via suppression of the non-canonical Wnt5a/JNK1 signaling pathway and NF-κB. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.